Search / 10 posts tagged p53

Biotech, RNAi, Alnylam Luke Timmerman wrote: A lot has been written about how Alnylam Pharmaceuticals, and plenty of other companies, see a gold mine in turning off problem genes through drugs based on the biological phenomenon called RNA interference, or RNAi.

EWS-FLI1 Suppresses NOTCH-Activated p53 in Ewing’s Sarcoma. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G, Schwentner R, Smrzka O, Muehlbacher K, Aryee DN, Kovar H. Cancer Res. 2008 Sep 1;68(17):7100-9.

Shares of Austin-based Introgen Therapeutics plunged 26 percent this morning after investors learned that the FDA has rejected its BLA for the cancer therapy Advexin. According to Introgen, regulators had rejected the BLA as incomplete. Introgen was seeking approval to use the drug--a p53 tumor suppressor therapy--to treat head and neck cancer.

Since we just mentioned skin coloration (here, in passing), and we have previously discussed how the p53 protein is involved with it (here), it's interesting that there is now more news on the subject.

P52 gene, arrows show locations of common mutations  (Image courtesy www.bioinf.org) Following on from my last article on using gene therapy for increasing survival in head and neck cancer, Professor Jack Roth, M.D., professor in M. D.

Thank you to Jennifer Texada at MD Anderson for bringing this great cancer treatment discovery to my attention…. (Image courtesy Introgen Therapeutics) A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S.

Oh god - can’t focus. It’s the last exam for the class which I have to take for my stupid grant on Thursday, so I have to remember large unnecessary diagrams full of acronyms and numbers and crap: When what I really want to do is go play Mario Kart write sexy articles about classical music for you all to read.

Study raises questions about prostate cancer therapies targeting... EurekAlert! - Cancer Wed, 04/30/2008 - 23:00 (Fred Hutchinson Cancer Research Center) Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor to activate its target receptor could

Millions of post-menopausal women use hormone replacement therapy (HRT) as a method to reduce symptoms associated with menopause. In a recent University of Missouri study, researchers found that one of the hormones used in HRT, a synthetic progestin, could be a major factor in promoting breast cancer.